Tumour ReviewTime for more optimism in metastatic breast cancer?
Introduction
Breast cancer (BC) is the most prevalent female malignancy and the second most common cause of death in developed countries. In 2013 in the United States, an estimated 234,580 women will be diagnosed with invasive BC and 40,030 will die from it [1]. In 2008, in Europe there were 424,800 new BC cases and 128,700 BC-related deaths [2]. Every year almost half a million women lose their lives to breast cancer [2]. Recent years have faced remarkable changes both in the treatment philosophy of metastatic breast cancer (MBC) and in the available therapies, contributing to improvements in survival rates and quality of life.
BC is a heterogeneous disease, characterised by deregulation of multiple cellular pathways, different morphology and sensitivity to various treatments. Better understanding of BC biology has led to targeted treatments against specific molecular subsets, resulting in improved outcomes. In a large single-institution retrospective study of 2091 women, after adjusting for patient and tumour characteristics, women with HER2+/ER+(luminal HER2+) disease treated with trastuzumab had 5 years’ survival similar to those with HER2-/ER+(luminal HER2−) tumours (29.7% vs. 31.3%, respectively), while the 5 years’ survival of women with luminal HER2+ disease who did not receive trastuzumab was significantly worse (14.5%) and similar to trastuzumab-treated women with HER2+/ER− disease (17.7%). Finally, women with HER2+/ER− disease who did not receive trastuzumab had only 8.9% 5 years’ survival, similar to that of triple negative (TN) patients (7.9%) [3].
Breast cancer subtypes also differ by the pattern of metastatic disease. In a large series of 3726 early BC patients from British Columbia bone was the most common metastatic site in all subtypes except basal-like tumours. Compared with luminal HER2−, luminal HER2+ and HER2+/ER− tumours were associated with significantly more brain, liver, and lung metastases, whereas basal-like tumours had higher rate of brain, lung, and distant nodal metastases but significantly less liver and bone metastases [4]. A strikingly high tendency of TN cancers to metastasize to brain was also seen in other series [5], [6], whereas luminal B tumours seem to be related to higher risk of bone metastases [7]. Median survival was dependent on the tumour subtype and ranged from 0.5 years for basal-like to 2.2 years for luminal HER2− tumours (p < 0.001) [4]. Several studies have also demonstrated significant differences in the timing of distant recurrence: oestrogen receptor negative (ER−) tumours tend to be associated with early relapse whereas ER+ tumours show a persistent late risk beyond 5 years [8], [9], [10]. In the British Columbia population, although at the 5-year time point HER2+/ER− patients had significantly higher relapse rate than luminal HER2+ tumours, this difference was lost at 15 years as a result of more late relapses in the latter group [4].
Selecting therapies in MBC requires therefore consideration not only of patient status and disease extent but also of the tumour molecular characteristics, defined by either genomic testing [11] or immunohistochemistry [12], [13], [14]. When considering survival improvements and potential areas of progress in MBC it is hence crucial to analyse each disease subtype separately.
Section snippets
Endocrine responsive (luminal) breast cancer
Luminal HER2-negative BC represents 60–65% of all newly diagnosed patients. Although prognosis in this subtype is generally good, still many women will relapse and luminal HER2-negative BC remains the most common subtype among MBC patients.
Conclusion
In spite of all the developments and the huge progress in our understanding of BC behaviour, MBC still remains an incurable disease, and still too few patients can be turned to a chronic, long-lasting condition. Apart from limitations related to disease biology, professionals caring for MBC patients face many (often unnecessary and avoidable) organizational and economic obstacles [140]. Additionally, in contrast to early BC, management of MBC is less frequently based on local or international
Conflict of interest statement
E. Senkus has reported advisory board for GlaxoSmithKline and AstraZeneca; travel support from Roche and Amgen. F. Cardoso has reported consultancy/research grants from Eisai, Roche, GlaxoSmithKline, Celgene, AstraZeneca, Novartis, Pfizer, Astellas, GE Oncology, Merck-Sharp, Merus, BV, Genentech; speaker’s bureau from Novartis, GlaxoSmithKline. O. Pagani has reported no conflict of interest.
References (140)
- et al.
Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen
Ann Oncol
(2007) - et al.
A review of the treatment of endocrine responsive metastatic breast cancer in postmenopausal women
Cancer Treat Rev
(2013) - et al.
Fulvestrant alone or with concomitant anastrozole vs. exemestane following progression on non-steroidal aromatase inhibitor-first results of the Sofea trial (cruke/03/021 and cruk/09/007) (isrctn44195747)
Eur J Cancer
(2012) - et al.
Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer
Eur J Cancer
(2012) - et al.
Effects of fulvestrant 750 mg in premenopausal women with oestrogen-receptor-positive primary breast cancer
Eur J Cancer
(2008) - et al.
What is triple-negative breast cancer?
Eur J Cancer
(2008) - et al.
Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome
Clin Breast Cancer
(2013) - et al.
Triple-negative breast cancer: therapeutic options
Lancet Oncol
(2007) - et al.
Triple-negative breast cancer – current status and future directions
Ann Oncol
(2009) - et al.
Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design
Clin Breast Cancer
(2009)
Oral poly(ADPribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Lancet
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
Lancet Oncol
Rational use of trastuzumab in metastatic and locally advanced breast cancer: implications of recent research
Breast
Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? a mono-institutional experience and systematic review of observational studies
Breast
Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the international breast cancer study group (IBCSG)
Ann Oncol
Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study
Lancet Oncol
CEREBEL (EGF111438): an open label randomized phase III study comparing the incidence of CNS metastases in patients (pts) with HER2+ metastatic breast cancer (MBC), treated with lapatinib plus capecitabine (LC) vs. trastuzumab plus capecitabine (TC)
Ann Oncol
Combining trastuzumab (Herceptin) with hormonal therapy in breast cancer: what can be expected and why?
Ann Oncol
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer – results of the eLEcTRA trial
Breast
1st International consensus guidelines for advanced breast cancer (ABC 1)
Breast
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
Ann Oncol
Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy
Ann Oncol
Activity of fulvestrant in HER2-overexpressing advanced breast cancer
Ann Oncol
Dutch breast cancer trialists’ group (BOOG). randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2(+) metastatic breast cancer: HERTAX trial
Clin Breast Cancer
Cancer statistics, 2013
CA Cancer J Clin
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008
Int J Cancer
Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review
J Clin Oncol
Metastatic behavior of breast cancer subtypes
J Clin Oncol
Subtypes of breast cancer show preferential site of relapse
Cancer Res
Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases
Cancer
Patterns of recurrence and outcome according to breast cancer subtypes in lymph node-negative disease: results from international breast cancer study group trials VIII and IX
J Clin Oncol
Annual hazard rates of recurrence for breast cancer after primary therapy
J Clin Oncol
Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
BMC Cancer
Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures
BMC Med Genomics
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the breast cancer association consortium studies
J Natl Cancer Inst
Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies
PLoS Med
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer
J Natl Cancer Inst
Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women (Review)
Fulvestrant: a review of its use in the management of hormone receptor-positive metastatic breast cancer in postmenopausal women
Drugs
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study
Breast Cancer Res Treat
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer
J Clin Oncol
FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer
J Clin Oncol
Combination anastrozole and fulvestrant in metastatic breast cancer
N Engl J Med
Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor–positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study
J Clin Oncol
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer
N Engl J Med
Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer
J Clin Oncol
Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials
J Clin Oncol
Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study
Anticancer Res
Phase II trial of anastrozole plus goserelin in the treatment of hormone receptor–positive, metastatic carcinoma of the breast in premenopausal women
J Clin Oncol
Phase II parallel group study showing comparable efficacy between premenopausal metastatic breast cancer patients treated with letrozole plus goserelin and postmenopausal patients treated with letrozole alone as first-line hormone therapy
J Clin Oncol
Cited by (62)
Surgery for liver metastases from primary breast cancer: A reconstructed individual patient data meta-analysis
2024, European Journal of Surgical OncologyNeem gum based pH responsive hydrogel matrix: A new pharmaceutical excipient for the sustained release of anticancer drug
2020, International Journal of Biological MacromoleculesRLIP inhibition suppresses breast-to-lung metastasis
2019, Cancer LettersCitation Excerpt :Breast cancer (BC) is one of the most common malignancies diagnosed in women, and metastatic BC maintains a high mortality rate despite improvement in clinical outcomes for patients with targeted primary tumors [1].
The incidence of atypical femoral fractures in breast cancer patients with bone metastases who received bisphosphonate treatment
2017, Journal of Orthopaedic Science